Greystone Associates       Home Contact Site Map

 NEWS & EVENTS

Research Reports Advisories News/Events About Greystone
 

 Transdermal  Delivery

After Recent Challenges, the U.S. Market for Transdermal Patches Set to Climb Back to $3 Billion by 2010

 

Practice Areas

 

Greystone Associates Analyzes the Impact of Generics, Post-launch Complications, and New Products on Demand and Revenue

(Amherst, NH) – The transdermal patch sector has been undergoing significant market stress as two flagship products with sales accounting for more than half the total market have lost momentum. Duragesic – the single largest transdermal drug delivery patch on the market in terms of current dollar value – has come under pressure from generic versions of the fentanyl patch (Mylan, Lavipharm), and seen an almost forty percent decrease in revenue from its 2004 peak.

The contraceptive patch segment has also seen its fortunes change dramatically. Ortho McNeil’s Ortho Evra contraceptive patch sales have been adversely affected by reported health risks associated with blood clots among women using the patch. In spite of these market sector setbacks which resulted in total U.S. revenue of less than $2.2 billion in 2006, this sector should rebound to slightly more than $3 billion by the end of the decade. Growth will be driven in large part by transdermal patch therapies for new indications, primarily in the area of neurology.

 Source: Greystone Associates

 

Go To Report Page

 

Related Topics

Active Transdermal Delivery

Microneedles in Medicine

Iontophoresis Transdermal Delivery

Transmucosal Drug Delivery

 

Additional Resources

Transdermal Delivery Pharmacokinetics Overview

Drug Delivery Report Catalog (PDF)